-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Clinical Discussant for Thalassemia

Program: Special-Interest Sessions
Session: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Monday, December 9, 2024, 4:30 PM-6:00 PM

Janet L. Kwiatkowski, MD

Children's Hospital of Philadelphia, Philadelphia, PA

Disclosures: Kwiatkowski: Bristol Myers Squibb: Consultancy; bluebird bio, Inc.: Consultancy, Research Funding; Chiesi: Consultancy; BioMarin: Consultancy; Agios: Consultancy, Research Funding; Vertex Pharmaceuticals: Consultancy; Forma Therapeutics: Consultancy, Research Funding; Editas Medicine: Research Funding; Pfizer: Research Funding; CRISPR/Vertex: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Silence Therapeutics: Consultancy; Apopharma: Research Funding; Novo-Nordisk: Consultancy.

See more of: ASH-FDA Joint Symposium II: Challenges and Innovations in Rare Diseases in Non-Malignant Hematology
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>